{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:16:37Z","timestamp":1790691397395,"version":"4.1.0"},"reference-count":204,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Psoriasis, a chronic immune-mediated inflammatory skin disorder affecting approximately 2-3% of the global population, manifests in distinct forms including plaque, pustular, and erythrodermic types. The pathogenesis involves complex interactions between genetic susceptibility, epigenetic modifications, and environmental triggers that disrupt immune homeostasis, particularly within the skin\u2019s epithelial immune microenvironment (EIME). This review examines the fundamental mechanisms of psoriasis from a \u2018bench\u2019 perspective, encompassing genetic triggers, immune cell contributions, cytokine cascades, and insights derived from multi-omics studies. It also incorporates emerging areas such as gut microbiota dysbiosis and neuro-immunological influences. Translational research linking these discoveries to clinical application is discussed, covering biomarker identification, comorbidity management, and the advancement of novel therapies. At the \u2018bedside\u2019, we evaluate current conventional treatments, targeted biologic agents (e.g., TNF-\u03b1, IL-17, and IL-23 inhibitors), and emerging modalities including JAK inhibitors, epigenetic modulators, and stem cell therapies. Challenges pertaining to efficacy, safety, and personalized medicine are addressed, alongside future directions emphasizing multi-omics integration and holistic immune targeting. Highlighting the critical role of the immune microenvironment, this narrative review underscores the translational progress driving towards improved patient outcomes.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1643418","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T05:45:32Z","timestamp":1756446332000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Skin immune microenvironment in psoriasis: from bench to bedside"],"prefix":"10.3389","volume":"16","author":[{"given":"Yi","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Qing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Bo","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-Li","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Jie","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Armstrong","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15382","article-title":"Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants","volume":"8","author":"Tsoi","year":"2017","journal-title":"Nat Commun"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102315","article-title":"Whole-genome DNA methylation in skin lesions from patients with psoriasis","volume":"104","author":"Zhang","year":"2019","journal-title":"J Autoimmun"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.det.2014.09.002","article-title":"The immunopathogenesis of psoriasis","volume":"33","author":"Kim","year":"2015","journal-title":"Dermatol Clin"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2012.15","article-title":"New insights of T cells in the pathogenesis of psoriasis","volume":"9","author":"Cai","year":"2012","journal-title":"Cell Mol Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.sder.2010.01.002","article-title":"Comorbidities in psoriasis patients","volume":"29","author":"Patel","year":"2010","journal-title":"Semin Cutan Med Surg"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2022.01.006","article-title":"Associations between psoriasis and mental illness: an update for clinicians","volume":"75","author":"Hedemann","year":"2022","journal-title":"Gen Hosp Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1590\/abd1806-4841.20153038","article-title":"Psoriasis: classical and emerging comorbidities","volume":"90","author":"Oliveira Mde","year":"2015","journal-title":"Bras Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: A review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000274","article-title":"New therapies for psoriasis and psoriatic arthritis","volume":"28","author":"Ritchlin","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub2","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"1","author":"Sbidian","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1086\/503821","article-title":"Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene","volume":"78","author":"Nair","year":"2006","journal-title":"Am J Hum Genet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jaut.2015.07.008","article-title":"The immunogenetics of psoriasis: A comprehensive review","volume":"64","author":"Harden","year":"2015","journal-title":"J Autoimmun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12375","article-title":"Heritability of psoriasis in a large twin sample","volume":"169","author":"L\u00f8nnberg","year":"2013","journal-title":"Br J Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jaut.2013.01.001","article-title":"Whole-genome DNA methylation in skin lesions from patients with psoriasis vulgaris","volume":"41","author":"Zhang","year":"2013","journal-title":"J Autoimmun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2016.12.002","article-title":"Epigenetics of psoriatic disease: A systematic review and critical appraisal","volume":"78","author":"Pollock","year":"2017","journal-title":"J Autoimmun"},{"key":"B21","doi-asserted-by":"publisher","first-page":"155657","DOI":"10.1016\/j.cyto.2021.155657","article-title":"LncRNA MEG3 suppresses PI3K\/AKT\/mTOR signalling pathway to enhance autophagy and inhibit inflammation in TNF-\u03b1-treated keratinocytes and psoriatic mice","volume":"148","author":"Tang","year":"2021","journal-title":"Cytokine"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2007.08.015","article-title":"Triggering psoriasis: the role of infections and medications","volume":"25","author":"Fry","year":"2007","journal-title":"Clin Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12670","article-title":"Psoriasis and smoking: A systematic review and meta-analysis","volume":"170","author":"Armstrong","year":"2014","journal-title":"Br J Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184347","article-title":"Risk factors for the development of psoriasis","volume":"20","author":"Kamiya","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nri2622","article-title":"Skin immune sentinels in health and disease","volume":"9","author":"Nestle","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nri3646","article-title":"Mechanisms regulating skin immunity and inflammation","volume":"14","author":"Pasparakis","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abq7991","article-title":"Spatial transcriptomics stratifies psoriatic disease severity by emergent cellular ecosystems","volume":"8","author":"Castillo","year":"2023","journal-title":"Sci Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0509736102","article-title":"Increase in TNF-\u03b1 and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)","volume":"102","author":"Lowes","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B29","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.jaci.2010.12.009","article-title":"Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong Th17\/Th1 T-cell responses","volume":"127","author":"H\u00e4nsel","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"5621","DOI":"10.1038\/ncomms6621","article-title":"The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis","volume":"5","author":"Lande","year":"2014","journal-title":"Nat Commun"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.165","article-title":"A subpopulation of CD163-positive macrophages is classically activated in psoriasis","volume":"130","author":"Fuentes-Duculan","year":"2010","journal-title":"J Invest Dermatol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"5310","DOI":"10.1038\/s41598-019-41655-7","article-title":"Monocytes\/Macrophages play a pathogenic role in IL-23 mediated psoriasis-like skin inflammation","volume":"9","author":"Wang","year":"2019","journal-title":"Sci Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"490","DOI":"10.4049\/jimmunol.1100123","article-title":"Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis","volume":"187","author":"Lin","year":"2011","journal-title":"J Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.02.816","article-title":"Myeloid-derived suppressor cells in psoriasis are an expanded population exhibiting diverse T-Cell-Suppressor mechanisms","volume":"136","author":"Cao","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jaci.2015.01.033","article-title":"Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis","volume":"136","author":"Mashiko","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.477","article-title":"Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis","volume":"134","author":"Villanova","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/jid.2008.194","article-title":"Psoriasis is characterized by accumulation of immunostimulatory and Th1\/Th17 cell-polarizing myeloid dendritic cells","volume":"129","author":"Zaba","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16172","article-title":"Impaired Langerhans cell migration in psoriasis is due to an altered keratinocyte phenotype induced by interleukin-17","volume":"178","author":"Eaton","year":"2018","journal-title":"Br J Dermatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090480","article-title":"Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8","volume":"206","author":"Ganguly","year":"2009","journal-title":"J Exp Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1340677","article-title":"Immune cells in the epithelial immune microenvironment of psoriasis: emerging therapeutic targets","volume":"14","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nature06116","article-title":"Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide","volume":"449","author":"Lande","year":"2007","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02376","article-title":"Neutrophils in psoriasis","volume":"10","author":"Chiang","year":"2019","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1998.00347.x","article-title":"Interleukin-17 and interferon-\u03b3 synergize in the enhancement of proinflammatory cytokine production by human keratinocytes","volume":"111","author":"Teunissen","year":"1998","journal-title":"J Invest Dermatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.09.037","article-title":"Biological effects of IL-26 on T cell\u2013mediated skin inflammation, including psoriasis","volume":"139","author":"Itoh","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41467-019-13756-4","article-title":"Neutrophil extracellular trap-associated RNA and LL37 enable self-amplifying inflammation in psoriasis","volume":"11","author":"Herster","year":"2020","journal-title":"Nat Commun"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.5114\/ceji.2024.143691","article-title":"Down-regulation of SHP2 promotes neutrophil autophagy and inhibits neutrophil extracellular trap formation to alleviate asthma through the ERK5 pathway","volume":"49","author":"Shi","year":"2024","journal-title":"Cent Eur J Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1578635","article-title":"The dual role of IL-17 in periodontitis regulating immunity and bone homeostasis","volume":"16","author":"Tang","year":"2025","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1038\/s41467-021-24352-w","article-title":"The RNase MCPIP3 promotes skin inflammation by orchestrating myeloid cytokine response","volume":"12","author":"Liu","year":"2021","journal-title":"Nat Commun"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.4c13533","article-title":"Enhance efferocytosis and block the macrophages\u2013platelets feedback loop for targeted treatment of psoriasis","volume":"19","author":"Liu","year":"2025","journal-title":"ACS nano"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.876515","article-title":"Alarmin cytokines as central regulators of cutaneous immunity","volume":"13","author":"Hasegawa","year":"2022","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.749626","article-title":"A traditional Chinese medicine formula danshen baibixiao ameliorates imiquimod-induced psoriasis-like inflammation in mice","volume":"12","author":"Jin","year":"2021","journal-title":"Front Pharmacol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03292.x","article-title":"Immunopathogenesis of psoriasis: focus on natural killer T cells","volume":"23","author":"Peternel","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1159\/000328011","article-title":"Natural killer cells in psoriasis","volume":"3","author":"Tobin","year":"2011","journal-title":"J Innate Immun"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.799560","article-title":"Dysregulated peripheral invariant natural killer T cells in plaque psoriasis patients","volume":"9","author":"Hu","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.jid.2019.12.013","article-title":"IL-17E (IL-25) and IL-17A differentially affect the functions of human keratinocytes","volume":"140","author":"Borowczyk","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0803721","article-title":"IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells","volume":"183","author":"Goodman","year":"2009","journal-title":"J Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302313","article-title":"Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis","volume":"192","author":"Cheuk","year":"2014","journal-title":"J Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1172\/JCI93396","article-title":"Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing \u03b1\u03b2 T cell clones","volume":"127","author":"Matos","year":"2017","journal-title":"J Clin Invest"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.627139","article-title":"Gamma delta T cells and their pathogenic role in psoriasis","volume":"12","author":"Qi","year":"2021","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100804","article-title":"Identification of a novel proinflammatory human skin-homing V\u03b39V\u03b42 T cell subset with a potential role in psoriasis","volume":"187","author":"Laggner","year":"2011","journal-title":"J Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.31266","article-title":"The immunological understanding on germinal center B cells in psoriasis","volume":"239","author":"Noor","year":"2024","journal-title":"J Cell Physiol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20232091","article-title":"A human STAT3 gain-of-function variant drives local Th17 dysregulation and skin inflammation in mice","volume":"221","author":"Toth","year":"2024","journal-title":"J Exp Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.immuni.2011.08.001","article-title":"Pivotal role of dermal IL-17-producing \u03b3\u03b4 T cells in skin inflammation","volume":"35","author":"Cai","year":"2011","journal-title":"Immunity"},{"key":"B65","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.immuni.2023.01.025","article-title":"Skin \u03b3\u03b4 T cell inflammatory responses are hardwired in the thymus by oxysterol sensing via GPR183 and calibrated by dietary cholesterol","volume":"56","author":"Frascoli","year":"2023","journal-title":"Immunity"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.05.002","article-title":"Natural and adaptive Foxp3+ regulatory T cells: more of the same or a division of labor","volume":"30","author":"Curotto de Lafaille","year":"2009","journal-title":"Immunity"},{"key":"B68","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s40001-023-01144-0","article-title":"Transcriptional regulation on effector T cells in the pathogenesis of psoriasis","volume":"28","author":"Qu","year":"2023","journal-title":"Eur J Med Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1016\/j.immuni.2023.06.021","article-title":"Obesity-induced dysregulation of skin-resident PPAR\u03b3+ Treg cells promotes IL-17A-mediated psoriatic inflammation","volume":"56","author":"Sivasami","year":"2023","journal-title":"Immunity"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2015.11.001","article-title":"Treatment of psoriasis with mesenchymal stem cells","volume":"129","author":"Chen","year":"2016","journal-title":"Am J Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.11.028","article-title":"Single-cell RNA sequencing of psoriatic skin identifies pathogenic Tc17 cell subsets and reveals distinctions between CD8+ T cells in autoimmunity and cancer","volume":"147","author":"Liu","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.08.048","article-title":"A skewed pool of resident T cells triggers psoriasis-associated tissue responses in never-lesional skin from patients with psoriasis","volume":"143","author":"Gallais S\u00e9r\u00e9zal","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B73","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/ni.3504","article-title":"CD69 controls L-Trp uptake through LAT1-CD98 and AhR-dependent IL-22 secretion in psoriasis","volume":"17","author":"Cibrian","year":"2016","journal-title":"Nat Immunol"},{"key":"B74","article-title":"MMP2hi fibroblasts regulate CD8+ T cell residency and inflammation via CD100 in psoriasis","volume":"191","author":"Du","year":"2024","journal-title":"Br J Dermatol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"269rv1","DOI":"10.1126\/scitranslmed.3010641","article-title":"Resident memory T cells in human health and disease","volume":"7","author":"Clark","year":"2015","journal-title":"Sci Transl Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/nri2586","article-title":"Structure and signalling in the IL-17 receptor family","volume":"9","author":"Gaffen","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2013.60","article-title":"IL-17 cytokines in immunity and inflammation","volume":"2","author":"Jin","year":"2013","journal-title":"Emerg Microbes Infect"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis","volume":"182","author":"van der Fits","year":"2009","journal-title":"J Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-303339","article-title":"Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells","volume":"117","author":"Dusseaux","year":"2011","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2017.01.006","article-title":"IL-17 signaling: The yin and the yang","volume":"38","author":"Amatya","year":"2017","journal-title":"Trends Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2013.03.014","article-title":"The activation and regulation of IL-17 receptor mediated signaling","volume":"62","author":"Song","year":"2013","journal-title":"Cytokine"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1400513111","article-title":"IL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms","volume":"111","author":"Ha","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-023-01828-z","article-title":"Decreased imiquimod-induced psoriasis-like skin inflammation in a novel Mvd F250S\/+ Knock-in mouse model","volume":"46","author":"La","year":"2023","journal-title":"Inflammation"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)00070-4","article-title":"Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12","volume":"13","author":"Oppmann","year":"2000","journal-title":"Immunity"},{"key":"B86","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.621956","article-title":"Major role of the IL17\/23 axis in psoriasis supports the development of new targeted therapies","volume":"12","author":"Bugaut","year":"2021","journal-title":"Front Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20060244","article-title":"IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis","volume":"203","author":"Chan","year":"2006","journal-title":"J Exp Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.01.025","article-title":"Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis","volume":"133","author":"Sofen","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.04.029","article-title":"IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis","volume":"144","author":"Krueger","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030451","article-title":"Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris","volume":"199","author":"Lee","year":"2004","journal-title":"J Exp Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2012.10.014","article-title":"Tumor necrosis factor","volume":"328","author":"Chu","year":"2013","journal-title":"Cancer Lett"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2007.00629.x","article-title":"Immunopathogenesis of psoriasis","volume":"16","author":"Sabat","year":"2007","journal-title":"Exp Dermatol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1172\/JCI12153","article-title":"A role for mitogen-activated protein kinase activation by integrins in the pathogenesis of psoriasis","volume":"108","author":"Haase","year":"2001","journal-title":"J Clin Invest"},{"key":"B96","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cytogfr.2014.10.009","article-title":"An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17","volume":"26","author":"Grine","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"key":"B97","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1016\/j.jid.2021.12.036","article-title":"TNFR2 depletion reduces psoriatic inflammation in mice by downregulating specific dendritic cell populations in lymph nodes and inhibiting IL-23\/IL-17 pathways","volume":"142","author":"Chandrasekharan","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.12.010","article-title":"Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis","volume":"86","author":"Murphy","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.08.001","article-title":"Tumor necrosis factor-\u03b1 inhibitor-induced psoriasis: Systematic review of clinical features, histopathological findings, and management experience","volume":"76","author":"Brown","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.847160","article-title":"Incidence of and risk factors for paradoxical psoriasis or psoriasiform lesions in inflammatory bowel disease patients receiving anti-TNF therapy: systematic review with meta-analysis","volume":"13","author":"Xie","year":"2022","journal-title":"Front Immunol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"11368","DOI":"10.1038\/s41598-018-29472-w","article-title":"RNA-seq and flow-cytometry of conventional, scalp, and palmoplantar psoriasis reveal shared and distinct molecular pathways","volume":"8","author":"Ahn","year":"2018","journal-title":"Sci Rep"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12610","article-title":"Regulation and function of interleukin-36 cytokines","volume":"281","author":"Bassoy","year":"2018","journal-title":"Immunol Rev"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2013.11.003","article-title":"Biology of IL-36 cytokines and their role in disease","volume":"25","author":"Gresnigt","year":"2013","journal-title":"Semin Immunol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.12.003","article-title":"IL-36 signaling is essential for psoriatic inflammation through the augmentation of innate immune responses","volume":"139","author":"Ohko","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301481","article-title":"IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin","volume":"192","author":"Foster","year":"2014","journal-title":"J Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.234","article-title":"Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis","volume":"131","author":"Carrier","year":"2011","journal-title":"J Invest Dermatol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013068","article-title":"Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis","volume":"365","author":"Marrakchi","year":"2011","journal-title":"N Engl J Med"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2011.07.022","article-title":"Mutations in IL36RN\/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis","volume":"89","author":"Onoufriadis","year":"2011","journal-title":"Am J Hum Genet"},{"key":"B109","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.3390\/ijms22094344","article-title":"Exploring the role of IL-36 cytokines as a new target in psoriatic disease","volume":"22","author":"Iznardo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B110","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2340\/00015555-2808","article-title":"Highlighting interleukin-36 signalling in plaque psoriasis and pustular psoriasis","volume":"98","author":"Furue","year":"2018","journal-title":"Acta dermato-venereologica"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1811317","article-title":"Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis","volume":"380","author":"Bachelez","year":"2019","journal-title":"N Engl J Med"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01378-8","article-title":"Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial","volume":"402","author":"Morita","year":"2023","journal-title":"Lancet"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2012.06.001","article-title":"IL-36 in psoriasis","volume":"12","author":"Towne","year":"2012","journal-title":"Curr Opin Pharmacol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.jaci.2014.05.046","article-title":"Humanized anti\u2013IFN-\u03b3 (HuZAF) in the treatment of psoriasis","volume":"135","author":"Harden","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cr.7310017","article-title":"Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don\u2019t know","volume":"16","author":"Shi","year":"2006","journal-title":"Cell Res"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190945","article-title":"GM-CSF in inflammation","volume":"217","author":"Hamilton","year":"2020","journal-title":"J Exp Med"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00559.x","article-title":"Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis","volume":"159","author":"Schafer","year":"2010","journal-title":"Br J Pharmacol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases","volume":"9","author":"Li","year":"2018","journal-title":"Front Pharmacol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"72","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018266","article-title":"Genome-wide expression profiling of five mouse models identifies similarities and differences with human psoriasis","volume":"6","author":"Swindell","year":"2011","journal-title":"PloS One"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1159\/000538993","article-title":"Challenges in psoriasis research: a systematic review of preclinical models","volume":"240","author":"Ubago-Rodr\u00edguez","year":"2024","journal-title":"Dermatology"},{"key":"B122","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/bjd.21245","article-title":"Patients with psoriasis have a dysbiotic taxonomic and functional gut microbiota","volume":"187","author":"Todberg","year":"2022","journal-title":"Br J Dermatol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S337031","article-title":"Gut and cutaneous microbiome featuring abundance of Lactobacillus reuteri protected against psoriasis-like inflammation in mice","volume":"14","author":"Chen","year":"2021","journal-title":"J Inflammation Res"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1430586","article-title":"Gut microbiota and psoriasis: pathogenesis, targeted therapy, and future directions","volume":"14","author":"Zou","year":"2024","journal-title":"Front Cell Infection Microbiol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"112928","DOI":"10.1016\/j.intimp.2024.112928","article-title":"Advances in the mechanism of action of short-chain fatty acids in psoriasis","volume":"141","author":"Zhang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1126\/science.1241165","article-title":"The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis","volume":"341","author":"Smith","year":"2013","journal-title":"Science"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13786","article-title":"Intestinal microbiota profiling and predicted metabolic dysregulation in psoriasis patients","volume":"27","author":"Chen","year":"2018","journal-title":"Exp Dermatol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s13555-020-00466-9","article-title":"Gut\u2013brain\u2013skin axis in psoriasis: A review","volume":"11","author":"Chen","year":"2021","journal-title":"Dermatol Ther"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.2127","article-title":"Association between Mediterranean anti-inflammatory dietary profile and severity of psoriasis: results from the NutriNet-Sant\u00e9 cohort","volume":"154","author":"Phan","year":"2018","journal-title":"JAMA Dermatol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9020353","article-title":"Gut-skin axis: Current knowledge of the interrelationship between microbial dysbiosis and skin conditions","volume":"9","author":"De Pessemier","year":"2021","journal-title":"Microorganisms"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens9060463","article-title":"Gut microbiome in psoriasis: An updated review","volume":"9","author":"Sikora","year":"2020","journal-title":"Pathogens"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-326789","article-title":"Gut microbiome and health: Mechanistic insights","volume":"71","author":"de Vos","year":"2022","journal-title":"Gut"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e37432","article-title":"Fecal microbiota transplantation for the treatment of chronic inflammatory skin diseases","volume":"10","author":"Wu","year":"2024","journal-title":"Heliyon"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg6007","article-title":"Adoptive Treg therapy with metabolic intervention via perforated microneedles ameliorates psoriasis syndrome","volume":"9","author":"Zhang","year":"2023","journal-title":"Sci Adv"},{"key":"B135","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3390\/pharmaceutics15020699","article-title":"Modulating inflammation-mediated diseases via natural phenolic compounds loaded in nanocarrier systems","volume":"15","author":"Rakotondrabe","year":"2023","journal-title":"Pharmaceutics"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1038\/nature13199","article-title":"Nociceptive sensory neurons drive interleukin-23-mediated psoriasiform skin inflammation","volume":"510","author":"Riol-Blanco","year":"2014","journal-title":"Nature"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08235.x","article-title":"Psoriasis: evolution of pathogenic concepts and new therapies through phases of translational research","volume":"157","author":"Guttman-Yassky","year":"2007","journal-title":"Br J Dermatol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/363159a0","article-title":"Regulation of Langerhans cell function by nerves containing calcitonin gene-related peptide","volume":"363","author":"Hosoi","year":"1993","journal-title":"Nature"},{"key":"B139","doi-asserted-by":"publisher","first-page":"2306772","DOI":"10.1002\/advs.202306772","article-title":"Cutaneous calcium\/calmodulin-dependent protein kinase II-\u03b3\u2013positive sympathetic nerves secreting norepinephrine dictate psoriasis","volume":"11","author":"Yu","year":"2024","journal-title":"Advanced Sci"},{"key":"B140","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jad.2023.05.059","article-title":"Evidence for a causal association between psoriasis and psychiatric disorders using a bidirectional Mendelian randomization analysis in up to 902,341 individuals","volume":"337","author":"Wang","year":"2023","journal-title":"J Affect Disord"},{"key":"B141","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.nrl.2020.12.007","article-title":"Association between psoriasis and dementia: A systematic review","volume":"39","author":"Zhao","year":"2024","journal-title":"Neurologia"},{"key":"B142","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12026-014-8517-0","article-title":"Effects of stress on immune function: the good, the bad, and the beautiful","volume":"58","author":"Dhabhar","year":"2014","journal-title":"Immunol Res"},{"key":"B143","doi-asserted-by":"publisher","first-page":"5288","DOI":"10.1038\/s41467-024-49577-3","article-title":"Sensory ASIC3 channel exacerbates psoriatic inflammation via a neurogenic pathway in female mice","volume":"15","author":"Huang","year":"2024","journal-title":"Nat Commun"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14071","article-title":"Role of neuroimmune circuits and pruritus in psoriasis","volume":"29","author":"Ayasse","year":"2020","journal-title":"Exp Dermatol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2009.09.033","article-title":"A meta-analysis of cytokines in major depression","volume":"67","author":"Dowlati","year":"2010","journal-title":"Biol Psychiatry"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1002\/art.38892","article-title":"Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease","volume":"67","author":"Scher","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.11.038","article-title":"HLA-C* 06: 02 genotype is a predictive biomarker of biologic treatment response in psoriasis","volume":"143","author":"Dand","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2024.2859","article-title":"Exploring the link between genetic predictors of cardiovascular disease and psoriasis","volume":"9","author":"Ramessur","year":"2024","journal-title":"JAMA Cardiol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1346687","article-title":"Identification of immunological patterns characterizing immune-related psoriasis reactions in oncological patients in therapy with anti-PD-1 checkpoint inhibitors","volume":"15","author":"Morelli","year":"2024","journal-title":"Front Immunol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19192","article-title":"Depression, a major comorbidity of psoriatic disease, is caused by metabolic inflammation","volume":"37","author":"Mrowietz","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B151","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/jdv.18044","article-title":"Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis","volume":"36","author":"Wu","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.2174\/1381612828666220201141915","article-title":"An innovative approach in nanotechnology-based delivery system for the effective management of psoriasis","volume":"28","author":"Parveen","year":"2022","journal-title":"Curr Pharm design"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2025.2472968","article-title":"Novel strategies in topical delivery for psoriasis treatment: nanocarriers and energy-driven approaches","volume":"22","author":"Lin","year":"2025","journal-title":"Expert Opin Drug Delivery"},{"key":"B154","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2174\/2589977513666210707114520","article-title":"IL-23\/Th17 axis: a potential therapeutic target of psoriasis","volume":"14","author":"Sharma","year":"2022","journal-title":"Curr Drug Res Rev Formerly: Curr Drug Abuse Rev"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.2463","article-title":"Noninferiority of 16-week vs 8-week guselkumab dosing in super responders for maintaining control of psoriasis: the GUIDE randomized clinical trial","volume":"160","author":"Eyerich","year":"2024","journal-title":"JAMA Dermatol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19341","article-title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy\u2013assessor-blinded clinical trial","volume":"184","author":"Warren","year":"2021","journal-title":"Br J Dermatol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adi2848","article-title":"A single-cell atlas of IL-23 inhibition in cutaneous psoriasis distinguishes clinical response","volume":"9","author":"Wu","year":"2024","journal-title":"Sci Immunol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejphar.2018.03.018","article-title":"Anti-IL-12\/IL-23p40 antibody ameliorates dermatitis and skin barrier dysfunction in mice with imiquimod-induced psoriasis-like dermatitis","volume":"828","author":"Takahashi","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.1338","article-title":"Biosimilars for the treatment of psoriasis: a systematic review of clinical trials and observational studies","volume":"159","author":"Phan","year":"2023","journal-title":"JAMA Dermatol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2142465","article-title":"Biologic insights from single-cell studies of psoriasis and psoriatic arthritis","volume":"22","author":"Jin","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S367744","article-title":"Bimekizumab for the treatment of psoriasis: a review of the current knowledge","volume":"12","author":"Ruggiero","year":"2022","journal-title":"Psoriasis: Targets Ther"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-00928-w","article-title":"Next-generation anti-IL-17 agents for psoriatic disease: A pipeline review","volume":"26","author":"Kim","year":"2025","journal-title":"Am J Clin Dermatol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae062","article-title":"A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis","volume":"191","author":"Cai","year":"2024","journal-title":"Br J Dermatol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20133","article-title":"Multi-treatment resistance to biological treatment in patients with psoriasis: Definitions and implications","volume":"39","author":"Henckens","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.11.068","article-title":"Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial","volume":"90","author":"Fiorillo","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0709-1","article-title":"Apremilast: a review in psoriasis and psoriatic arthritis","volume":"77","author":"Keating","year":"2017","journal-title":"Drugs"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1288714","article-title":"Safety evaluation of apremilast for the treatment of psoriasis","volume":"16","author":"Dattola","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae014","article-title":"Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials","volume":"190","author":"Lebwohl","year":"2024","journal-title":"Br J Dermatol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1177\/24755303231201336","article-title":"Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis","volume":"8","author":"Kingston","year":"2023","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.2701","article-title":"Tyrosine kinase 2 inhibition with zasocitinib (TAK-279) in psoriasis: a randomized clinical trial","volume":"160","author":"Armstrong","year":"2024","journal-title":"JAMA Dermatol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.10.085","article-title":"Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor\u2013modulating agent","volume":"84","author":"Bissonnette","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15931","article-title":"Tapinarof for the treatment of psoriasis","volume":"35","author":"Nogueira","year":"2022","journal-title":"Dermatologic Ther"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.12.823","article-title":"Pellino-1 promotes intrinsic activation of skin-resident IL-17A\u2013producing T cells in psoriasis","volume":"151","author":"Kim","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S504639","article-title":"Using siRNA-based anti-inflammatory lipid nanoparticles for gene regulation in psoriasis","volume":"20","author":"Zeng","year":"2025","journal-title":"Int J Nanomedicine"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.917939","article-title":"A machine learning approach to predict remission in patients with psoriatic arthritis on treatment with secukinumab","volume":"13","author":"Venerito","year":"2022","journal-title":"Front Immunol"},{"key":"B177","doi-asserted-by":"publisher","first-page":"e23375","DOI":"10.1096\/fj.202201709RRRR","article-title":"IL-21 promoting angiogenesis contributes to the development of psoriasis","volume":"38","author":"Han","year":"2024","journal-title":"FASEB J"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21048","article-title":"Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult-to-treat population","volume":"187","author":"Mastorino","year":"2022","journal-title":"Br J Dermatol"},{"key":"B179","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s40257-024-00887-8","article-title":"Predicting the time to relapse following withdrawal from different biologics in patients with psoriasis who responded to therapy: A 12-year multicenter cohort study","volume":"25","author":"Huang","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.4129","article-title":"Psoriasis risk with immune checkpoint inhibitors","volume":"161","author":"To","year":"2025","journal-title":"JAMA Dermatol"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-025-01278-7","article-title":"Saturated fatty acid-induced neutrophil extracellular traps contribute to exacerbation and biologic therapy resistance in obesity-related psoriasis","volume":"22","author":"Xia","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.02.008","article-title":"Psoriasis harbors multiple pathogenic type 17 T-cell subsets: Selective modulation by risankizumab","volume":"155","author":"Kim","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B183","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1038\/s41467-025-56719-8","article-title":"GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets","volume":"16","author":"Dand","year":"2025","journal-title":"Nat Commun"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae179","article-title":"Gasdermin E-mediated keratinocyte pyroptosis participates in the pathogenesis of psoriasis by promoting skin inflammation","volume":"191","author":"Li","year":"2024","journal-title":"Br J Dermatol"},{"key":"B185","doi-asserted-by":"publisher","first-page":"2400107","DOI":"10.1002\/advs.202400107","article-title":"FGF12 positively regulates keratinocyte proliferation by stabilizing MDM2 and inhibiting p53 activity in psoriasis","volume":"11","author":"Wang","year":"2024","journal-title":"Advanced Sci"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01160-y","article-title":"Targeting STING in dendritic cells alleviates psoriatic inflammation by suppressing IL-17A production","volume":"21","author":"Sun","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01164-6","article-title":"Real-world long-term effectiveness of risankizumab among patients with moderate-to-severe psoriasis: analysis from an international medical chart review (RAPID) study","volume":"14","author":"Pinter","year":"2024","journal-title":"Dermatol Ther"},{"key":"B188","doi-asserted-by":"publisher","first-page":"113581","DOI":"10.1016\/j.jconrel.2025.113581","article-title":"Dendritic lipopeptide-based transdermal siRNA delivery systems for effective non-invasive therapy in psoriasis","volume":"381","author":"Ma","year":"2025","journal-title":"J Controlled Release"},{"key":"B189","doi-asserted-by":"publisher","first-page":"122915","DOI":"10.1016\/j.lfs.2024.122915","article-title":"The safety and efficacy of adipose tissue-derived exosomes in treating mild to moderate plaque psoriasis: A clinical study","volume":"353","author":"Mohseni Meybodi","year":"2024","journal-title":"Life Sci"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.10.035","article-title":"Bruton\u2019s tyrosine kinase (BTK) and matrix metalloproteinase-9 (MMP-9) regulate NLRP3 inflammasome-dependent cytokine and neutrophil extracellular trap responses in primary neutrophils","volume":"155","author":"Leal","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae205","article-title":"Fibroblasts with high matrix metalloproteinase 2 expression regulate CD8+ T-cell residency and inflammation via CD100 in psoriasis","volume":"191","author":"Dong","year":"2024","journal-title":"Br J Dermatol"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1172\/JCI183219","article-title":"Ferroptosis of select skin epithelial cells initiates and maintains chronic systemic immune-mediated psoriatic disease","volume":"135","author":"Vats","year":"2025","journal-title":"J Clin Invest"},{"key":"B193","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.3390\/jcm10173822","article-title":"Skin-resident memory T cells: pathogenesis and implication for the treatment of psoriasis","volume":"10","author":"Vu","year":"2021","journal-title":"J Clin Med"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.8b02330","article-title":"Nanoparticle-assisted transcutaneous delivery of a signal transducer and activator of transcription 3-inhibiting peptide ameliorates psoriasis-like skin inflammation","volume":"12","author":"Kim","year":"2018","journal-title":"ACS nano"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.842813","article-title":"Small extracellular vesicles derived from MSCs have immunomodulatory effects to enhance delivery of ASO-210 for psoriasis treatment","volume":"10","author":"Zhang","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S376216","article-title":"Nanomaterial-based drug delivery systems: A new weapon for cancer immunotherapy","volume":"17","author":"Jiang","year":"2022","journal-title":"Int J nanomed"},{"key":"B197","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3390\/biomedicines13040781","article-title":"Novel small-molecule treatment and emerging biological therapy for psoriasis","volume":"13","author":"Li","year":"2025","journal-title":"Biomedicines"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1136\/egastro-2023-100012","article-title":"Horizon scanning: new and future therapies in the management of inflammatory bowel disease","volume":"1","author":"Kumar","year":"2023","journal-title":"EGastroenterology"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.09.020","article-title":"From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies","volume":"70","author":"Hugh","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01668","article-title":"Psoriasis, cardiovascular events, and biologics: lights and shadows","volume":"9","author":"Caiazzo","year":"2018","journal-title":"Front Immunol"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01984","article-title":"The role of nociceptive neurons in the pathogenesis of psoriasis","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1201912","article-title":"Psoriasis immunometabolism: progress on metabolic biomarkers and targeted therapy","volume":"10","author":"Sarandi","year":"2023","journal-title":"Front Mol Biosci"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-020-00380-3","article-title":"Deciphering the association between psoriasis and obesity: current evidence and treatment considerations","volume":"9","author":"Paroutoglou","year":"2020","journal-title":"Curr Obes Rep"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2020.09.023","article-title":"Psoriasis: pathological mechanisms, current pharmacological therapies, and emerging drug delivery systems","volume":"25","author":"Rapalli","year":"2020","journal-title":"Drug Discov Today"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1643418\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T05:45:34Z","timestamp":1756446334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1643418\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":204,"alternative-id":["10.3389\/fimmu.2025.1643418"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1643418","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"article-number":"1643418"}}